*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
Caspase 9 (cleaved Asp330) antibody detects endogenous levels of fragment of activated Caspase 9 resulting from cleavage adjacent to Asp330.
PBS (without Mg²⁺ and Ca²⁺) pH 7.4, 150mM NaCl, 0.02% sodium azide, 50% glycerol
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Batch dependent (Please refer to the vial label for the specific concentration.)
The antiserum was produced against synthesized peptide derived from human Caspase 9 (281-330).
Purified by antigen-affinity chromatography
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
APAF3 , CASP9 , ICELAP6 , MCH6 , PPP1R56 , caspase 9 , Caspase 9
This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein can undergo autoproteolytic processing and activation by the apoptosome, a protein complex of cytochrome c and the apoptotic peptidase activating factor 1; this step is thought to be one of the earliest in the caspase activation cascade. This protein is thought to play a central role in apoptosis and to be a tumor suppressor. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2013]